Bear-like human hibernation could enable ambitious proposals for Mars.
On Monday, the European Space Agency published a report explaining how hibernation could help humanity get to Mars. The agency explained that when bears hibernate, they use fewer resources without letting their muscles and bones go to waste.
For a multi-month trip to Mars, it could help a crew complete their trip with reduced stress levels and fewer medical complications. Crew members would enter pods, administer a drug, and let the ship handle operations for most of the flight.
Elon Musk has always said that Neuralink, the company he created in 2016 to build brain-computer interfaces, would do amazing things: Eventually, he says, it aims to allow humans to interact seamlessly with advanced artificial intelligence through thought alone. Along the way, it would help to cure people with spinal cord injuries and brain disorders ranging from Parkinson’s to schizophrenia.
Now the company is approaching a key test: a human clinical trial of its brain-computer interface (BCI). In December, Musk told a conference audience that “we hope to have this in our first humans” in 2022. In January, the company posted a job listing for a clinical trial director, an indication that it may be on track to meet Musk’s suggested timeline.
Musk has put the startup under unrelenting pressure to meet unrealistic timelines, these former employees say. “There was this top-down dissatisfaction with the pace of progress even though we were moving at unprecedented speeds,” says one former member of Neuralink’s technical staff, who worked at the company in 2019. “Still Elon was not satisfied.” Multiple staffers say company policy, dictated by Musk, forbade employees from faulting outside suppliers or vendors for a delay; the person who managed that relationship had to take responsibility for missed deadlines, even those outside their control.
When I was ten years old, I discovered computers. My first machine was a PDP-10 mainframe system at the medical center where my father worked. I taught myself to write simple programs in the BASIC computer language. Like any ten-year-old, I was especially pleased to discover games on the computer. One game was simply labeled “ADVENT.” I opened it and saw:
You are standing at the end of a road before a small brick building. Around you is a forest. A small stream flows out of the building and down a gully.
I figured out that I could move around with commands like “go north” and “go south.” I entered the building and got food, water, keys, a lamp. I wandered outside and descended through a grate into a system of underground caves. Soon I was battling snakes, gathering treasures, and throwing axes at pesky attackers. The game used text only, no graphics, but it was easy to imagine the cave system stretching out below ground. I played for months, roaming farther and deeper, gradually mapping out the world.
Geri-Care issued a recall for some aspirin and acetaminophen bottles that are not child-resistant, posing a poisoning risk.
Aspirin and acetaminophen are over-the-counter drugs that countless people have in their medicine cabinets. Many people use them to alleviate pain and reduce fevers, and these drugs might be the first course of action when exhibiting such symptoms. That’s what makes them popular purchases with consumers. And that’s why buyers should pay extra close attention to recalls that involve aspirin and acetaminophen products.
A new recall action involves bottles of Geri-Care Pharmaceuticals aspirin and acetaminophen, as they pose a risk of poisoning to children who might get their hands on these common drugs.
The machine-learning model could help scientists speed the development of new medicines.
This technique could help scientists better understand some biological processes that involve protein interactions, like DNA replication and repair; it could also speed up the process of developing new medicines.
“Deep learning is very good at capturing interactions between different proteins that are otherwise difficult for chemists or biologists to write experimentally. Some of these interactions are very complicated, and people haven’t found good ways to express them. This deep-learning model can learn these types of interactions from data,” says Octavian-Eugen Ganea, a postdoc in the MIT Computer Science and Artificial Intelligence Laboratory (CSAIL) and co-lead author of the paper.
Ganea’s co-lead author is Xinyuan Huang, a graduate student at ETH Zurich. MIT co-authors include Regina Barzilay, the School of Engineering Distinguished Professor for AI and Health in CSAIL, and Tommi Jaakkola, the Thomas Siebel Professor of Electrical Engineering in CSAIL and a member of the Institute for Data, Systems, and Society. The research will be presented at the International Conference on Learning Representations.
Machine-learning model could help scientists speed the development of new medicines.
The AI nanny is here! In a new feat for science, robots and AI can now be paired to optimise the creation of human life. In a Matrix-esque reality, robotics and artificial intelligence can now help to develop babies with algorithms and artificial wombs.
Reported by South China Morning Post, Chinese scientists in Suzhou have developed the new technology. However, there are worries surrounding the ethics of actually artificially growing human babies.
Accelerating Research To Prevent & Cure Disease — Dr. Kevin Perrott, Ph.D., Founder & CEO, OpenCures; Co-Founder & Treasurer, SENS Research Foundation
Dr. Kevin Perrott, Ph.D. is Founder and CEO, OpenCures (https://opencures.org/), Adjunct Professor, University of Alberta, Co-Founder and Advisor, Oisin Biotechnologies, President, of Global Healthspan Policy Institute, and Co-Founder and Treasurer, SENS Research Foundation.
Kevin is a successful entrepreneur and owner of the largest motorcycle and snowmobile dealership in Canada, Riverside Honda and Skidoo Sales in Edmonton, Alberta. He became a cancer survivor, an experience which clearly highlighted the deficiencies of the current health technology development paradigm where the customer has almost no input in the development of their own health solutions. Armed with the realization that nothing is more valuable than health and the time to enjoy it with those you love, Kevin resolved to put his energies towards addressing these deficiencies.
In 2003, Kevin joined Aubrey de Grey and David Gobel to form the Methuselah Foundation which offered competitive prizes for advances in longevity science. A few years later he became a co-founder with Aubrey de Grey and others of SENS Research Foundation to develop interventions able to repair or make harmless the damage that accumulates and underlies multiple age-related disorders. Mostly recently, Kevin formed OpenCures as a for-benefit corporation helping individuals perform self-directed research, generate data, and focus the value of data on the health solutions they are interested in.
Kevin has authored and co-authored several peer-reviewed articles all focused on accelerating the science underlying the development of therapies for degenerative diseases. He is a co-founder of multiple non-profit and for-profit entities whose missions are aligned with that purpose.
With the emergence of the COVID-19 pandemic, humans have become reliant on personal protection equipment, or PPE, more and more with each wave of infection. While single-use face masks make up a large portion of PPE around the world, not much thought has been given to the proper disposal of these products.
While these products are crucial in our fight against COVID-19, they undoubtedly take a toll on the environment, ending up in landfills and oceans, giving off toxic gases. In only 2020, 52 billion face masks were made and 1.56 billion of them ended up in our oceans. they’re low-cost and disposable.
